Relevant Financial Interest Index
As a provider accredited by the Accreditation council for Continuing Medical Education, ASCRS must ensure balance, independence, objectivity, and scientific rigor in all its individually or jointly provided activities.
All individuals participating in an activity designated for CME credit must disclose any financial interest or relationship with an ineligible company that produces, markets, sells, resells, or distributes ophthalmic products/devices/drugs or services used on or by patients that are discussed in an educational presentation or lack thereof. Financial interest can include such things as grants or research support, consultant, stockholder, member of speaker’s bureau, et.
The intent of this disclosure is not to disqualify anyone from participating, but to provide the program committee with information so they can design and implement a balanced, independent, and scientific educational activity. The Financial Interest Index provides information to attendees, so they can make their own judgement regarding the interest or relationship and the materials presented. A complete listing of relations disclosed, and their corresponding codes are below.
|
Category |
Code |
Description |
|
Consultant/Advisor |
C |
I receive consultants' fees or paid advisory boards, speakers bureaus or fees for attending a meeting from an Ineligible Entity or provide practice management/marketing services to ophthalmic practices (within the past 24 months). |
|
Employee |
E |
I am a part-time or full-time employee of an Ineligible Entity (commercial interest) that produces, markets, sells, resells, or distributes ophthalmic products/devices/drugs or services related to patient clinical care or I have equity ownership/stock options/investment interest in a privately held company that produces, markets, sells, resells, or distributes ophthalmic products/devices/drugs or services related to patient clinical care. |
|
Spouse/Partner |
S |
My spouse or partner has a financial relationship with an Ineligible Entity that produces, markets, resells or distributes ophthalmic products/devices/drugs or services related to patients clinical care- encompassing royalties, investment, consulting/speaker's bureau, research grants, travel reimbursement or employment. |
|
Research/Grant Support |
R |
My research is fully or partially funded by an Ineligible Entity that produces, markets, resells, or distributes ophthalmic products/devices/drugs or services related to patient clinical care. |
|
Lecture Fees |
L |
My lecture fees (honoraria), travel fees or reimbursements when speaking at the invitation of an Ineligible Entity have been paid or subsidized by a company that produces, markets, resells or distributes ophthalmic products/devices/drugs or services related to patient care. |
|
Product/Patent/Royalty |
P |
I earn a royalty or derive other financial gain from an ophthalmic product or service. |
|
Equity Owner/Investor |
O |
I have an investment interest/equity ownership/stock options in a publicly traded company that produces, markets, sells, resells, or distributes ophthalmic products/devices/drugs or services related to patient clinical care. |
Patti Barkey, COE has no relevant financial interests.
Deborah Davis, COE has no relevant financial interests.
Nicole Fram, MD is a consultant/advisor for Alcon and RxSight. She receives lecture fees from Alcon and RxSight.
Carrie Jacobs, COE is a consultant/advisor for Alcon and RxSight.
Matt Jensen is a consultant/advisor for RxSight.
Jaime Johannesen has no relevant financial interests.
Richard Lindstrom, MD is a consultant/advisor for Alcon, Bausch & Lomb, and Lenstec. He is an equity owner/investor in Lenstec. He has a product/patent/royalty with Bausch & Lomb.
Vance Thompson, MD is a consultant/advisor for Alcon, Bausch & Lomb, BVI, Johnson & Johnson, LENSAR, Rayner, RxSight, STAAR and Zeiss. He receives research/grant support from Alcon, Bausch & Lomb, BVI, Johnson & Johnson, Rayner, RxSight, STAAR, and Zeiss. He receives lecture fees from BVI, Johnson & Johnson, and RxSight. He is an equity owner/investor in LENSAR, Rayner, and RxSight.
Richard Tipperman, MD is a consultant/advisor for Alcon.
Robert Weinstock, MD is a consultant/advisor for Alcon, Bausch & Lomb, BVI, Johnson & Johnson, and LENSAR. He receives lecture fees from Bausch & Lomb, BVI, and LENSAR. He is an equity owner/investor in RxSight.
William Wiley, MD is a consultant/advisor for Alcon, Atia Vision, Bausch & Lomb, BVI, Johnson & Johnson, Rayner, STAAR, and Zeiss. He receives research/grant support from Alcon, Bausch & Lomb, BVI, Johnson & Johnson, STAAR, and Zeiss. He receives lecture fees from Alcon.
Blake Williamson, MD has no relevant financial interests.
Dagny Zhu, MD is a consultant/advisor for Alcon, Bausch & Lomb, Johnson & Johnson, LENSAR, Lenstec, and STAAR. She receives research/grant support from Alcon.
Crista Parker, Carrie Braden, Lindsay Kunz, Nicole Hanson-Emerson, Angela Nichols, ASCRS Staff, have no financial interests.
All of the relevant financial relationships for these individuals have been mitigated.